Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Repurposing 4-phenylbutyrate as new treatment for osteogenesis imperfecta.
| Reference number | 2025-01796 |
| Coordinator | Karolinska Institutet - Karolinska Institutet, Institutionen för klinisk vetenskap, intervention och teknik |
| Funding from Vinnova | SEK 2 999 418 |
| Project duration | January 2026 - December 2028 |
| Status | Ongoing |
| Venture | European Joint Programme on Rare Diseases |
| Call | International collaborations with preclinical therapy studies of rare diseases |
Last updated 18 December 2025
Reference number 2025-01796
